Joseph Stich
Human Resources Officer bei SURMODICS, INC.
Vermögen: 2 Mio $ am 31.03.2024
Profil
Joseph J.
Stich's current job(s) include Senior Vice President-Human Resources at Surmodics, Inc. since 2010 and Vice President & General Manager at In Vitro Diagnostics since 2011.
Mr. Stich's former job(s) include Vice President-Sales & Business Development at MGI PHARMA, Inc. from 2005 to 2009, Vice President-Corporate Development at Abraxis BioScience, Inc. from 2009 to 2010, and President & Chief Operating Officer at Pharmaceutical Corp.
of America.
Mr. Stich's education history includes an MBA from Rockhurst University in 1996 and an undergraduate degree from the University of Wisconsin-Whitewater in 1988.
Bekannte Unternehmensbeteiligungen
Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
---|---|---|---|---|
SURMODICS, INC.
0,43% | 04.12.2023 | 61 796 ( 0,43% ) | 2 Mio $ | 31.03.2024 |
Aktive Positionen von Joseph Stich
Unternehmen | Position | Beginn |
---|---|---|
SURMODICS, INC. | Human Resources Officer | 01.04.2020 |
In Vitro Diagnostics
In Vitro Diagnostics Medical SpecialtiesHealth Technology Part of Siemens AG, In Vitro Diagnostics is a medical diagnostic testing American company. The private company is located in the US. The company was founded in 1986. In Vitro Diagnostics was acquired by Dade Behring Holdings, Inc. from EIDP, Inc. on May 08, 1996 for $450 million. | Corporate Officer/Principal | 01.08.2011 |
Ehemalige bekannte Positionen von Joseph Stich
Unternehmen | Position | Ende |
---|---|---|
Abraxis BioScience, Inc.
Abraxis BioScience, Inc. Pharmaceuticals: MajorHealth Technology Abraxis Bioscience, Inc. develops therapeutics for cancer, infectious diseases and other critical illnesses. Its development platform uses nanoparticle albumin-bound technology to deliver drugs to tumors that produce SPARC. Abraxene, the first protein-based nanoparticle chemotherapeutic compound, is FDA approved for treating metastatic breast cancer. Abraxis Bioscience is focused on expanding the use of Abraxene and developing other drug candidates utilizing the same technology. Abraxene is approved for marketing in over 35 countris and the company has manufacturing facilities in the United States and Switzerland. Abraxis Bioscience was organized in 2007 from the oncology and research businesses of American Pharmaceutical Partners, Inc. and is headquartered in Los Angeles, CA. | Corporate Officer/Principal | 01.01.2010 |
MGI PHARMA, Inc.
MGI PHARMA, Inc. Pharmaceuticals: MajorHealth Technology MGI PHARMA, INC. develops, manufactures & markets pharmaceutical and medical products for therapeutic markets. The company's products include Aloxi injection, Dacogen, Gliadel water, Hexalen capsules, and Salagen Tablets. It has alliances with Helsinn Healthcare SA, Kissei Pharmaceutical Co. Ltd., Dainippon Pharmaceutical Co. Ltd., Pfizer, Inc. and Novartis Pharma AG. The company was founded in 1979 and is headquartered in Bloomington, MN. | Sales & Marketing | 01.01.2009 |
Pharmaceutical Corp. of America | President | - |
Ausbildung von Joseph Stich
Rockhurst University | Masters Business Admin |
University of Wisconsin-Whitewater | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Börsennotierte Unternehmen | 1 |
---|---|
SURMODICS, INC. | Health Technology |
Private Unternehmen | 4 |
---|---|
MGI PHARMA, Inc.
MGI PHARMA, Inc. Pharmaceuticals: MajorHealth Technology MGI PHARMA, INC. develops, manufactures & markets pharmaceutical and medical products for therapeutic markets. The company's products include Aloxi injection, Dacogen, Gliadel water, Hexalen capsules, and Salagen Tablets. It has alliances with Helsinn Healthcare SA, Kissei Pharmaceutical Co. Ltd., Dainippon Pharmaceutical Co. Ltd., Pfizer, Inc. and Novartis Pharma AG. The company was founded in 1979 and is headquartered in Bloomington, MN. | Health Technology |
Abraxis BioScience, Inc.
Abraxis BioScience, Inc. Pharmaceuticals: MajorHealth Technology Abraxis Bioscience, Inc. develops therapeutics for cancer, infectious diseases and other critical illnesses. Its development platform uses nanoparticle albumin-bound technology to deliver drugs to tumors that produce SPARC. Abraxene, the first protein-based nanoparticle chemotherapeutic compound, is FDA approved for treating metastatic breast cancer. Abraxis Bioscience is focused on expanding the use of Abraxene and developing other drug candidates utilizing the same technology. Abraxene is approved for marketing in over 35 countris and the company has manufacturing facilities in the United States and Switzerland. Abraxis Bioscience was organized in 2007 from the oncology and research businesses of American Pharmaceutical Partners, Inc. and is headquartered in Los Angeles, CA. | Health Technology |
In Vitro Diagnostics
In Vitro Diagnostics Medical SpecialtiesHealth Technology Part of Siemens AG, In Vitro Diagnostics is a medical diagnostic testing American company. The private company is located in the US. The company was founded in 1986. In Vitro Diagnostics was acquired by Dade Behring Holdings, Inc. from EIDP, Inc. on May 08, 1996 for $450 million. | Health Technology |
Pharmaceutical Corp. of America |